Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial
Nouhravesh N, Clare R, Wojdyla D, Anstrom K, Velazquez E, Greene S, Pitt B, Mentz R, Psotka M. Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial. European Heart Journal 2024, 45: ehae666.1068. DOI: 10.1093/eurheartj/ehae666.1068.Peer-Reviewed Original ResearchKCCQ-CSSTertile 1Diuretic doseHeart failureAll-cause mortalityTertile 3Tertile 2Diuretic strategyKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreDoses of loop diureticsHigh doses of furosemideComposite all-cause mortalityBaseline to monthDose of furosemideClinical summary scoreRisk of adverse eventsInteraction p valuePost hoc analysisFurosemide equivalentsLoop diureticsOpen-labelMedian ageNo significant differenceClinical outcomesStudy endpointDiuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM‐HF trial
Nouhravesh N, Greene S, Clare R, Wojdyla D, Anstrom K, Velazquez E, Pitt B, Mentz R, Psotka M. Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM‐HF trial. European Journal Of Heart Failure 2024 PMID: 39363809, DOI: 10.1002/ejhf.3458.Peer-Reviewed Original ResearchLoop diuretic doseDiuretic doseHeart failureDiuretic typeKCCQ-CSSClinical outcomesKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreGroup 2High dosesHigher loop diuretic dosesGroup 3High doses of furosemideDose group 2Associated with increased riskDose of furosemideClinical summary scoreSecondary clinical outcomesPatient-reported outcomesPost hoc analysisFurosemide equivalentsDose groupDischarge doseTRANSFORM-HFClinical eventsGroup 1